Please upgrade your browser.
They asked the panel to consider whether a new trial was needed to better assess risk versus benefit, given that other treatments are available.
2 May 2013, Budapest
Streams live 3-4 May from Hungary
This year’s grant recipient of the Kidney Cancer Association (KCA) Eugene P. Schonfeld Research Award is Dr. Eliezer Van Allen, of Dana-Farber Cancer Institute, whose project is titled “Dissecting clinical resistance to PI3K inhibitors in PIK3CA or PTEN-mutant cancers.”
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
We retrospectively analyzed metastatic renal cell carcinoma (RCC) patients treated with 3 targeted agents. Patients started the sequence with a tyrosine kinase inhibitor (TKI), sunitinib or sorafenib, and were divided into 2 groups based on the order in which they received the other reciprocal TKI and everolimus (EVE): TKI-TKI-EVE group (nÂ =Â 19) and TKI-EVE-TKI group (nÂ =Â 14).
Are you PatientSmart? Get in on the ground floor of something that has the potential to fundamentally transform medicine. Best of all, it's FREE! www.PatientSmart.org(SM).
Today, I list 4 biopharmas I feel offer strong upside potential in the short and medium term. With these catalysts quickly approaching, we can expect some nice shorter-term appreciation under normal market conditions. I feel the 4 stocks I list here are also strong speculation investments.
Results with personalized immunotherapy support phase III study, authors say...
Anyone who lived or worked at Camp Lejeune between 1957 and 1987 and have any of these conditions should contact the VA Hospital or the Wilson County Veteran's Service Office at 615-444-2460.
The incidence and consequences of positive surgical margins after partial nephrectomy are important issues in the management of localized renal cell carcinoma. A recent population-based study demonstrates a slightly higher rate of positive margins...
|Powered by NeonCRM|